Executive & Leadership Team
Close
Jürgen Horn
Chief Executive Officer
Role
CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company.
Experience
15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for global markets with a focus to transfer and apply innovative technologies from human biotechnology to advance veterinary medicine.
Previous
Novartis Animal Health, Novartis Institute for Biomedical Research, Elanco/Lilly, Nexvet
Education
Dr. med. vet., Ludwig Maximilians University Munich, Germany
PhD, Royal Veterinary College, University of London, UK
EMBA, London Business School, UK & Columbia Business School, NYC, US
Close
William Brondyk
Chief Scientific Officer
Role
Develop and execute a research strategy to generate innovative and transformative biotherapeutics for the Animal Health market.
Experience
20+ years of experience in developing protein therapeutics for oncology indications, immune-mediated diseases, infectious diseases, rare diseases and reproductive health and contraception.
Previous
Ohana Biosciences, Sanofi, Genzyme and Serono
Education
PhD in Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison
Close
Colin Giles
Chief Development Officer
Role
Clinical and Regulatory Affairs, passionate about bringing Invetx’s portfolio of innovative veterinary biotherapeutics through the regulatory process to be available to practicing veterinarians and their patients.
Experience
35 years of experience in the management of R&D in the Animal Health Industry including many years in senior leadership positions; focused on bringing innovative veterinary medicines to the marketplace.
Previous
Pfizer Animal Health (now Zoetis), Nexvet Biopharma, Independent Consultant
Education
BVetMed, Royal Veterinary College, University of London, UK
PhD, Royal Veterinary College, University of London, UK
Close
Chi-Ting Huang
Senior Director, CMC
Role
Implementing state-of-the-art manufacturing and development technologies to bring pioneering biotherapeutics to animal health.
Experience
20 years of experience developing biotherapeutics. Lead development teams for the production of several novel biotherapeutics (e.g. biosimilars, antibody-drug conjugates, highly glycosylated fusion proteins, TGF-beta proteins). Experience spans the initial IND for luspatercept as well as characterization for the commercialization of the Infuse(TM) Bone Graft.
Previous
Surface Oncology, Momenta Pharmaceuticals, Acceleron Pharma, Immunogen Inc., and Genetics Institute/Wyeth Biopharma
Education
BS, University of Illinois – Urbana
PhD, University of Minnesota – Twin Cities
Close
Lisa Bruce
Director, Program Management
Role
Oversee the development and execution of all Invetx programs by assigning milestones, tracking processes, and ensuring every team has what they need to complete programs on time and within budget.
Experience
20+ years of experience in various roles including biotech program management, clinical study project management, R&D research (both industry and academic), marketing & business development.
Previous
Stealth Biotherapeutics, Frenova Renal Research (part of Fresenius Medical Care), Pierce Biotechnology, Genzyme Corporation, Sigma Chemical Company, and Jewish Hospital at Washington University School of Medicine
Education
BS, University of Illinois, Champaign-Urbana, IL
Advisors
Close
Madhusudan Natarajan
Role
Scientific Advisor, Ad-hoc consultant
Advisor and consultant to Invetx from the ideation stage of the company transitioning to membership on the Scientific Advisory Board.
Head of the Rare Diseases Drug Discovery Unit at Takeda
Experience
Two decades of experience in human pharmaceutical development (Pfizer, Shire/Takeda), startups (Physiome Sciences) and academic research (Asst. Professor, University of Texas Southwestern Medical Center in Dallas) studying basic biological questions underpinning biology in multiple diseases and development of therapeutic approaches to address them.
Education
PhD in Neurobiology, Northwestern University, USA
BEng Electronics & Communication Engineering, University of Madras, India
Close
Rebecca Sendak
Role
Scientific Advisor
Head (SVP) of the Global Large Molecules Research Platform, Sanofi
Experience
20+ years of experience in biologics CMC (chemistry, manufacturing and controls) at Genzyme and Sanofi, from cell line development through GMP drug product manufacturing. Supported the development and commercialization of several biologics currently on the market.
Education
PhD in Biophysical Chemistry, Cornell University
Bachelor of Arts, Biology and Chemistry, University of Vermont
Board of Directors
Close
Phil Austin
Role
Director
Managing Partner, Anterra Capital
Founder and Managing Partner at Anterra Capital, currently leading their US office and Life Sciences investment team.
Experience
15+ years of consulting and investment experience initially in industrial biotech with McKinsey & Company and Atlas Venture, then more recently at Anterra Capital where his investment portfolio focuses on the application of life sciences technologies across agriculture, animal health, and nutritional wellness.
Previous
McKinsey & Co, Atlas Ventures, Rabo Ventures
Education
MEng Chemical Engineering & Pharmaceutical Chemistry, Heriot Watt University Edinburgh, UK
Close
Shaun Rodriguez
Role
Director
Director of Life Science Research, Casdin Capital
Serves on the board of several Casdin portfolio companies
Previous
Director and Senior Research Analyst at Cowen and Company, Associate with the Partners Innovation Fund and Business Development group at Partners Healthcare
Education
PhD in Biological Sciences, Harvard University
BS, University of Maine
MS, Tufts University
Close
Henry Skinner
Role
Director
Senior Vice President, Venture, Tekla Capital
Previous
Vice President and Deputy Head and Managing Director of the Novartis Venture Fund
Executive Director, Head Strategic Alliances at Novartis Institutes for Biomedical Research
Chief Executive Officer at SelectX Pharmaceuticals
President and Chief Executive Officer at NeoGenesis Pharmaceuticals Technology Acquisitions and Operations, Pfizer
Education
BS and MS in Biology/Biotechnology, Worcester Polytechnic Institute
MS in Biochemistry and PhD in Microbiology, University of Illinois
Postdoctoral in Molecular and Human Genetics, Baylor College of Medicine
Close
Maarten Goossens
Role
Observer
Founding Principal, Anterra Capital
Experience
10+ years of investment experience initially in M&A and VC with Rabobank focused on the agriculture and food industries, then more recently at Anterra Capital focused on life science and digital technologies across agriculture, animal health, and nutritional wellness.
Previous
Rabobank M&A and Rabo Private Equity
Education
Drs. MSc., Business Administration, Free University Amsterdam
Mini-MBA, Entrepreneurship, London School of Economics
Close
Kevin Huang
Role
Observer
Head of Strategy and Investment, WuXi Biologics
Leading strategic investment and corporate collaboration to support business growth, coordinate and drive internal business operation and improvement.
Experience
10+ years of experience in biologics drug development and manufacturing, life science investment banking and equity research, and management consulting.
Previous
Bristol-Myers Squibb, Morgan Stanley, Roland Berger
Education
PhD, University of Illinois College of Pharmacy
MS, University of Minnesota
BS, Peking University, CHN